Reactions 1444 - 23 Mar 2013 S Rufinamide Weight loss: 7 case reports A study identified four women and three men, aged 18-31 years, who developed weight loss during adjunctive treatment with rufinamide for epilepsy. The patients received rufinamide 800–2400 mg/day [routes not stated]. After 3–12 weeks, weight loss had become apparent in all seven patients. Investigations revealed a weight loss of 3.7–14 kg (BMI change of 7.3–18.7%). Due to weight loss, rufinamide was discontinued in four patients. Three of these regained 2.1–5 kg, but one did not regain the lost weight. Of the remaining three patients, two continued receiving rufinamide; one of these was given a dosage reduction, after which the woman regained 5kg. The other had stopped taking the drug due to lack of efficacy; she also regained some weight after this change. Rufinamide was re-initiated after withdrawal in two patients. One developed recurrent weight loss, and rufinamide was stopped again; the other had no new weight loss. Author comment: "[T]his study provides evidence that [rufinamide] can be associated with clinically significant weight loss in adult patients. Mourand I, et al. Dramatic weight loss with rufinamide. Epilepsia 54: e5-e8, No. 1, Jan 2013. Available from: URL: http://dx.doi.org/10.1111/ j.1528-1167.2012.03579.x - France 803084696 1 Reactions 23 Mar 2013 No. 1444 0114-9954/10/1444-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Rufinamide

Download PDF Report

Upload
tien-tien
View
212
Download
0

Embed Size (px)

Citation preview

Reactions 1444 - 23 Mar 2013

SRufinamide

Weight loss: 7 case reportsA study identified four women and three men, aged

18-31 years, who developed weight loss during adjunctivetreatment with rufinamide for epilepsy.

The patients received rufinamide 800–2400 mg/day [routesnot stated]. After 3–12 weeks, weight loss had becomeapparent in all seven patients. Investigations revealed a weightloss of 3.7–14 kg (BMI change of 7.3–18.7%).

Due to weight loss, rufinamide was discontinued in fourpatients. Three of these regained 2.1–5 kg, but one did notregain the lost weight. Of the remaining three patients, twocontinued receiving rufinamide; one of these was given adosage reduction, after which the woman regained 5kg. Theother had stopped taking the drug due to lack of efficacy; shealso regained some weight after this change.

Rufinamide was re-initiated after withdrawal in two patients.One developed recurrent weight loss, and rufinamide wasstopped again; the other had no new weight loss.

Author comment: "[T]his study provides evidence that[rufinamide] can be associated with clinically significantweight loss in adult patients.Mourand I, et al. Dramatic weight loss with rufinamide. Epilepsia 54: e5-e8, No. 1,Jan 2013. Available from: URL: http://dx.doi.org/10.1111/j.1528-1167.2012.03579.x - France 803084696